Gang Liu | Stem Cell Therapy | Best Researcher Award

Prof. Dr. Gang Liu | Stem Cell Therapy | Best Researcher Award

University-Town Hospital of Chongqing Medical University | China

AUTHOR PROFILE

SCOPUS ID

🏥DR. GANG LIU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Liu Gang embarked on his medical journey with a strong commitment to excellence in clinical medicine and translational research. After completing his medical degree in China, he pursued postdoctoral training (2008–2010) at the Division of Pulmonary and Critical Care Medicine, Long Island Jewish Medical Center, affiliated with the Albert Einstein College of Medicine in New York, USA. This critical early exposure to international clinical and research environments laid a strong foundation for his future leadership in emergency and critical care medicine.

🩺PROFESSIONAL ENDEAVORS

Dr. Liu currently serves as Chief Physician and Deputy Director at the Department of Emergency Medicine, University Town Hospital, affiliated with Chongqing Medical University. In parallel, he holds a vital administrative role as a Party Committee Member, contributing to strategic hospital governance.

Over the past two decades, Dr. Liu has risen through academic and clinical ranks, now holding titles such as Professor and Chief Physician in Critical Care Medicine, affirming his standing as a national leader in emergency and intensive care services.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON PEDIATRIC CRITICAL CARE MEDICINE

Though Dr. Liu is recognized primarily for his work in adult emergency medicine, his recent research interest has extended into Pediatric Critical Care Medicine, especially in areas intersecting with:

  • Pediatric Sepsis

  • Multi-organ Dysfunction Syndrome (MODS) in Children

  • Early detection and immune modulation in pediatric ICU patients

  • Neonatal emergency protocols during systemic infections

He has led cross-disciplinary initiatives to integrate pediatric-specific protocols into broader critical care workflows, optimizing early recognition and organ support strategies for critically ill pediatric patients in resource-variable settings.

🌍IMPACT AND INFLUENCE

Dr. Liu’s influence reaches national and regional health policy circles, particularly through his roles as:

  • Vice President, Hospital Safety Production Branch, National Association of Health Industry Management

  • Deputy Chair, Security and Protection Committee, Chongqing Hospital Association

Through these positions, he has helped shape emergency care infrastructure, establish hospital safety protocols, and train future critical care leaders, particularly in Western China—a focus of the “Western Region Healthcare Technical Backbone Talent Development Program” he was selected for in 2011.

🏆ACADEMIC CITES, ACCOLADES AND RECOGNITION

Dr. Liu has authored or co-authored numerous peer-reviewed articles, particularly in the domains of sepsis pathophysiology, organ injury, and critical care systems management. His academic work has been:

  • Cited over 1,000 times, reflecting robust clinical relevance and research translation.

  • Recognized in both Chinese national journals and international platforms, particularly for contributions to sepsis immunopathology and ICU systems optimization.

He was also selected for advanced ICU training at Peking University People’s Hospital, one of China’s leading tertiary institutions.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Liu is actively mentoring the next generation of emergency physicians and critical care researchers. He is involved in:

  • Designing pediatric emergency simulation training programs

  • Publishing ICU practice manuals that are being adopted in Chongqing province and beyond

  • Leading multi-center trials on pediatric sepsis resuscitation protocols

His long-term goal is to bridge the gap between adult and pediatric critical care, creating holistic emergency care ecosystems in resource-limited settings.

🧬CONCLUSION

Dr. Liu Gang, MD is a visionary leader in China’s critical and emergency medicine landscape, with a growing footprint in Pediatric Critical Care Medicine. His integrative approach, combining clinical excellence, hospital management, and research acumen, positions him as a catalyst for transformative healthcare solutions in both adult and pediatric critical care.

📊🔬NOTABLE PUBLICATION:

VNS facilitates the neurological function recovery after ischemia/reperfusion injury by regulating the A1/A2 polarization of astrocytes through the NMU-NMUR2 pathway

Authors: X. Jiang, Wendi Yang, Gang Liu, Changqing Li, Sheng Li

Journal: Neurochemistry International

Year: 2025

Mr. Toshitaka Hirano | Malignancy | Best Researcher Award

Mr. Toshitaka Hirano | Malignancy | Best Researcher Award

Pfizer Japan Inc | Japan

AUTHOR PROFILE

ORCID ID

🏫 EARLY ACADEMIC PURSUITS

Mr. Toshitaka Hirano pursued his education in Japan, specializing in fields related to oncology and pharmaceutical sciences. His early academic years were marked by a strong commitment to understanding the mechanisms of malignancy and its risk factors, laying the foundation for his influential career.

💼 PROFESSIONAL ENDEAVORS

Currently associated with Pfizer, Mr. Hirano has established himself as a leading expert in the risk factor analysis of malignancy. His role includes conducting advanced research, collaborating with global teams, and integrating pharmaceutical innovation with clinical practice.

🧬 CONTRIBUTIONS AND RESEARCH FOCUS

Mr. Hirano’s research is focused on identifying malignancy risk factors, particularly in patients with chronic conditions like rheumatoid arthritis. His studies examine the interplay between biological, environmental, and genetic factors contributing to cancer development. He has significantly advanced understanding in areas such as:

  • Immunogenicity risk associated with biologics
  • Cardiovascular events in rheumatic disease patients
  • Safety and effectiveness of novel therapies like tofacitinib

🌏 IMPACT AND INFLUENCE

Mr. Hirano’s work has had a profound impact on both clinical and research landscapes:

  • Policy and Practice: His findings inform public health guidelines and pharmaceutical strategies.
  • Patient Outcomes: Through his research, he has contributed to safer and more effective treatments for vulnerable populations.
  • International Collaboration: His global outreach ensures the dissemination of knowledge and best practices.

📚 ACADEMIC CITES

Mr. Hirano’s scholarly work is widely cited in high-impact journals, demonstrating its relevance and importance. Key publications include articles in International Journal of Rheumatic Diseases, Frontiers in Immunology, and Modern Rheumatology, highlighting his expertise in malignancy risk within rheumatic populations.

🏆 LEGACY AND FUTURE CONTRIBUTIONS ON MALIGNANCY

As a trailblazer in the field, Mr. Hirano is building a legacy of innovation and dedication to improving cancer outcomes. His future efforts aim to:

  • Develop predictive models for malignancy risks.
  • Enhance personalized medicine approaches.
  • Mentor the next generation of researchers in oncology and pharmaceutical sciences.

📌 OTHER IMPORTANT TOPICS

🔍 INTERDISCIPLINARY INTEGRATION

Mr. Hirano’s work bridges multiple fields, including oncology, immunology, and rheumatology, showcasing the value of a holistic research approach.

🌟 MENTORSHIP AND TEAM LEADERSHIP

He plays an active role in guiding young researchers and fostering collaborative environments that drive innovation.

🔔 PATIENT-CENTERED FOCUS

By emphasizing real-world data and patient-centered outcomes, Mr. Hirano ensures his work directly benefits those in need.

✨ CONCLUSION

Mr. Toshitaka Hirano’s dedication to malignancy risk analysis exemplifies the power of focused research to drive meaningful change. His work at Pfizer and beyond demonstrates a commitment to innovation, collaboration, and improving global health. With a legacy rooted in impactful research and a vision for a healthier future, Mr. Hirano continues to inspire and lead in the fight against cancer.

📊🔬NOTABLE PUBLICATION:
  • 1️⃣ Risk Factors Associated With Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis in a Real-World Setting in Japan
    • Authors: Kunihiro Yamaoka, Sugiyama N, Hoshi M, Jo JY, Kichul Shin, Hirano T
    • Journal: International Journal of Rheumatic Diseases
    • Year: 2024

    2️⃣ Individual and Population-Level Variability in HLA-DR Associated Immunogenicity Risk of Biologics Used for the Treatment of Rheumatoid Arthritis

    • Authors: Sugiyama N, Terry FE, Gutierrez AH, Hirano T, Hoshi M, Mizuno Y, Martin W, Yasunaga S, Niiro H, Fujio K, et al.
    • Journal: Frontiers in Immunology
    • Year: 2024

    3️⃣ Six-Month Safety and Effectiveness of Tofacitinib in Patients With Rheumatoid Arthritis in Japan: Interim Analysis of Post-Marketing Surveillance

    • Authors: Masataka Kuwana, Sugiyama N, Momohara S, Atsumi T, Takei S, Naoto Tamura, Masayoshi Harigai, Fujii T, Matsuno H, Takeuchi T, et al.
    • Journal: Modern Rheumatology
    • Year: 2024